Menu

Wolfson Institute of Preventive Medicine

Search - ZOO
Search - K2
Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Attila Lorincz, BsC (Dublin); PhD (Dublin)

Professor of Molecular Epidemiology

Centre for Cancer Prevention
email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0) 20 7882 3540

Profile

Attila Lorincz

I received a doctorate in genetics from Trinity College, University of Dublin, Ireland. While a research fellow at the University of California, Santa Barbara I discovered that yeast cdc28 is a protein kinase and the prototype of human cell cycle cdk kinases.

During later research on human papillomavirus I found several important and novel carcinogenic HPV types, including HPV31, HPV35, HPV45, HPV52 and HPV56, and pioneered the initial use of HPV DNA testing for clinical diagnostics.
My team produced the first HPV test to be FDA-approved for patients in 1988 and for general population cervical precancer screening in 2003. My research output also includes the development of a simple robust HPV assay for resource-limited regions.
I was lead author on a large randomized clinical trial to validate self-sampling with HPV testing as an efficient screening approach to prevent cervical cancer in a developing region.

My ongoing research interests include the epigenomics of prostate, breast and cervical cancers. Recently my team have developed diagnostic and prognostic cancer biomarkers based on DNA methylation assays.
A new classifier combining HPV and human genes is a leading contender as a triage test for women infected by carcinogenic HPV types, while a different methylation classifier is prognostic of death in men with prostate cancer.
Work ongoing in the Molecular Epidemiology Laboratory is also focused on next generation deep sequencing and in elucidating the comparative epigenomic systems of selected human cancers.

I have written more than 240 peer-reviewed papers and 45 patents related to diagnostic and prognostic testing.

The American Venereal Disease Association gave me their 1994 Achievement Award.

Queen Mary University of London received THE TIMES Award 2012 for UK research project of the year, related to my MARCH randomized clinical trial.

Currently I serve as Editor-in-Chief of Expert Reviews in Molecular Diagnostics and as Associate Editor of Cancer Biomarkers.

Return to top